Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy, Safety and Tolerability Study of TV-1106 in Growth Hormone-Deficient Adults Who Are Not Current Users of rhGH Treatment
Conditions
Interventions
TV-1106
Placebo
Locations
33
United States
Teva Investigational Site 13102
Artesia, California, United States
Teva Investigational Site 13127
Fountain Valley, California, United States
Teva Investigational Site 13126
Fountain Valley, California, United States
Teva Investigational Site 13103
Miami, Florida, United States
Teva Investigational Site 13118
Miami, Florida, United States
Teva Investigational Site 13123
Miami, Florida, United States
Start Date
April 30, 2015
Primary Completion Date
December 31, 2015
Completion Date
December 31, 2015
Last Updated
January 24, 2022
NCT07333521
NCT00227253
NCT06109935
NCT05230550
NCT05796440
NCT04970654
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions